focus -WSS

focus

author：explore 2025-09-30 21:22:25 - browse：54

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Novavax promises a turnaround & Lilly roils the obesity market
Next article： The most pressing bird flu mysteries scientists want answered

entertainment

WSS

As Maui death toll rises, number of missing remains unclear

Medicare Advantage's lean provider networks lead CMS complaints

FDA approves first treatment for ultra

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Evacuations in place as 3 wildfires burn in eastern Washington state

Hilary expected to bring catastrophic, life

focus

focus

focus

Medical leaders decry Supreme Court decision on affirmative action

Structure Therapeutics oral GLP

Guidelines to prevent youth baseball injuries need more muscle

Listen: Racing for gene therapy & a pioneering approval

23andMe had bad news about my health. I wish a person had delivered it

Hilary expected to bring catastrophic, life

State Dept. review finds Biden bears some blame for Afghanistan failures

Elevance PBM president out as customers face prescription chaos

Guidelines to prevent youth baseball injuries need more muscle

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

leisure time

Eli Lilly’s Zepbound improved liver scarring in mid

Living with Hashimoto's and celiac disease, and med school, too

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Sutter Health’s antitrust win overturned by appeals court

The boys, now 6, who are gene therapy’s ‘edge case’ problem

Ukraine taking heavy casualties 10 weeks into its counteroffensive

focus

entertainment

focus

entertainment